1. Search Result
Search Result
Results for "

CDDP

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17394
    Cisplatin
    385+ Cited Publications

    cis-Platinum; CDDP; cis-Diaminodichloroplatinum

    DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-17393
    Carboplatin
    40+ Cited Publications

    NSC 241240

    DNA Alkylator/Crosslinker Autophagy DNA/RNA Synthesis Cancer
    Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
    Carboplatin
  • HY-100690

    NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer .
    NSC16168
  • HY-17393S

    NSC 241240-d4

    Isotope-Labeled Compounds DNA Alkylator/Crosslinker Autophagy DNA/RNA Synthesis Cancer
    Carboplatin-d4 is the deuterium labeled Carboplatin. Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
    Carboplatin-d4
  • HY-17394R

    cis-Platinum (Standard); CDDP (Standard); cis-Diaminodichloroplatinum (Standard)

    DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Cancer
    Cisplatin (Standard) is the analytical standard of Cisplatin. This product is intended for research and analytical applications. Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin (Standard)
  • HY-146080

    Apoptosis Cancer
    Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .
    Antitumor agent-61
  • HY-149918

    Microtubule/Tubulin Apoptosis Cancer
    Antiproliferative agent-23 is a microtubule-destabilizing agent (MDA) and efficiently disturbes the tubulin-microtubule system. Antiproliferative agent-23 induces apoptosis via a mitochondrion-dependent pathway by downregulating the Bcl-2 protein, upregulating Bax and Cyt c proteins, and activating the caspase cascade. Antiproliferative agent-23 initiates reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin resistant cancer cell line) via the PERK/ATF4/CHOP signaling pathway. Antiproliferative agent-23 has anti-tumor activity .
    Antiproliferative agent-23
  • HY-15150G

    R428 (GMP); BGB324 (GMP)

    TAM Receptor Cancer
    Bemcentinib (R428) GMP is an orally active and selective inhibitor of Axl with an IC50 of 14 nM .
    Bemcentinib (GMP)
  • HY-158156

    NF-κB Apoptosis Cancer
    NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models. .
    NF-κB-IN-16
  • HY-139696

    Aldose Reductase Cancer
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells .
    AKR1B10-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: